Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting now · Phase 2

Conditions studied: Classical Hodgkin Lymphoma

In brief

The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r/r cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy regimens (ICE, DHAP). Synergistic effects of conventional agents with checkpoint inhibition may facilitate a highly effective therapy with limited toxicity, which might eventually substitute the very toxic high-dose chemotherapy (HDCT).

Key facts

Study ID

NCT04838652

Run by

University of Cologne

People needed

29

Starts

2024-03-05

Expected to finish

2028-05-01

Last updated by the study team

2024-08-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed first relapse of cHL or primary refractory cHL

You may not qualify if…

• Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma

Where it is running

• 1st Department of Medicine, Cologne University Hospital — Cologne, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.